Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Lung Cancer

Free Subscription Articles published in J Clin Invest Retrieve available abstracts of 47 articles: HTML format

Single Articles

May 2024
1. MILLS GB, Labrie M
   Enhancing anticancer activity of macrophages through rational drug combinations.
   J Clin Invest. 2024;134:e180512.
   PubMed     Abstract available
   
   
   April 2024
2. HAYASHI H, Chamoto K, Hatae R, Kurosaki T, et al
   Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade.
   J Clin Invest. 2024;134:e168318.
   PubMed     Abstract available
   
   
   
3. TAN AC, Cook SL, Khasraw M
   Soluble immune-checkpoint factors: a potential immunotherapy biomarker.
   J Clin Invest. 2024;134:e179352.
   PubMed     Abstract available
   
   
   March 2024
4. VACCARO K, Allen J, Whitfield TW, Maoz A, et al
   Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction.
   J Clin Invest. 2024;134:e169315.
   PubMed     Abstract available
   
   
   
5. CHEN Z, Vallega KA, Wang D, Quan Z, et al
   DNA topoisomerase II inhibition potentiates osimertinib's therapeutic efficacy in EGFR-mutant non-small cell lung cancer models.
   J Clin Invest. 2024 Mar 7:e172716. doi: 10.1172/JCI172716.
   PubMed     Abstract available
   
   
   January 2024
6. PEYVANDI S, Bulliard M, Yilmaz A, Kauzlaric A, et al
   Tumor-educated Gr1+CD11b+ cells drive breast cancer metastasis via OSM/IL6-JAK-induced cancer cell plasticity.
   J Clin Invest. 2024 Jan 18:e166847. doi: 10.1172/JCI166847.
   PubMed     Abstract available
   
   
   
7. GHANBAR MI, Suresh K
   Pulmonary toxicity of immune checkpoint immunotherapy.
   J Clin Invest. 2024;134:e170503.
   PubMed     Abstract available
   
   
   December 2023
8. JING N, Zhang K, Chen X, Liu K, et al
   ADORA2A-driven proline synthesis triggers epigenetic reprogramming in neuroendocrine prostate and lung cancers.
   J Clin Invest. 2023;133:e168670.
   PubMed     Abstract available
   
   
   
9. WANG S, Iyer R, Han X, Wei J, et al
   CRISPR screening identifies the deubiquitylase ATXN3 as a PD-L1-positive regulator for tumor immune evasion.
   J Clin Invest. 2023;133:e167728.
   PubMed     Abstract available
   
   
   November 2023
10. MAKINEN N, Meyerson M
    Genomic insights into the mechanisms of FGFR1 dependency in squamous cell lung cancer.
    J Clin Invest. 2023;133:e174171.
    PubMed     Abstract available
    
    
    October 2023
11. LIU S, Saunders M, Mak TW
    Chemical carcinogens: implications for cancer treatment.
    J Clin Invest. 2023;133:e174319.
    PubMed     Abstract available
    
    
    
12. HUANG M, Xia Y, Li K, Shao F, et al
    Carcinogen exposure enhances cancer immunogenicity by blocking the development of an immunosuppressive tumor microenvironment.
    J Clin Invest. 2023;133:e166494.
    PubMed     Abstract available
    
    
    
13. WANG T, Dong Y, Huang Z, Zhang G, et al
    Antioxidants stimulate BACH1-dependent tumor angiogenesis.
    J Clin Invest. 2023;133:e169671.
    PubMed     Abstract available
    
    
    September 2023
14. KONEN JM, Rodriguez BL, Wu H, Fradette JJ, et al
    Autotaxin suppresses cytotoxic T cells via LPAR5 to promote anti-PD-1 resistance in non-small cell lung cancer.
    J Clin Invest. 2023;133:e163128.
    PubMed     Abstract available
    
    
    August 2023
15. MALCHERS F, Nogova L, van Attekum MH, Maas L, et al
    Somatic rearrangements causing oncogenic ectodomain deletions of FGFR1 in squamous cell lung cancer.
    J Clin Invest. 2023 Aug 22:e170217. doi: 10.1172/JCI170217.
    PubMed     Abstract available
    
    
    July 2023
16. ATTIG J, Pape J, Doglio L, Kazachenka A, et al
    Human endogenous retrovirus onco-exaptation counters cancer cell senescence through calbindin.
    J Clin Invest. 2023;133:e164397.
    PubMed     Abstract available
    
    
    June 2023
17. NARDI F, Perurena N, Schade AE, Li ZH, et al
    Co-targeting a MYC-eIF4A survival axis improves the efficacy of KRAS inhibitors in lung cancer.
    J Clin Invest. 2023 Jun 29:e167651. doi: 10.1172/JCI167651.
    PubMed     Abstract available
    
    
    April 2023
18. SALMON M, Alvarez-Diaz R, Fustero-Torre C, Brehey O, et al
    Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas.
    J Clin Invest. 2023;133:e164413.
    PubMed     Abstract available
    
    
    
19. HU Z, Yu X, Ding R, Liu B, et al
    Glycolysis drives STING signaling to facilitate dendritic cell antitumor function.
    J Clin Invest. 2023;133:e166031.
    PubMed     Abstract available
    
    
    March 2023
20. JASPERS JE, Khan JF, Godfrey WD, Lopez AV, et al
    IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models.
    J Clin Invest. 2023 Mar 23:e166028. doi: 10.1172/JCI166028.
    PubMed     Abstract available
    
    
    February 2023
21. TAN X, Xiao GY, Wang S, Shi L, et al
    EMT-activated secretory and endocytic vesicular trafficking programs underlie a vulnerability to PI4K2A antagonism in lung cancer.
    J Clin Invest. 2023 Feb 9:e165863. doi: 10.1172/JCI165863.
    PubMed     Abstract available
    
    
    January 2023
22. WANG S, Rong R, Yang DM, Fujimoto J, et al
    Features of tumor-microenvironment images predict targeted therapy survival benefit in patients with EGFR-mutant lung cancer.
    J Clin Invest. 2023;133:e160330.
    PubMed     Abstract available
    
    
    
23. HU H, Cheng R, Wang Y, Wang X, et al
    Oncogenic KRAS signaling drives evasion of innate immune surveillance in lung adenocarcinoma by activating CD47.
    J Clin Invest. 2023;133:e153470.
    PubMed     Abstract available
    
    
    
24. DING L, Chen X, Zhang W, Dai X, et al
    Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling.
    J Clin Invest. 2023;133:e154754.
    PubMed     Abstract available
    
    
    December 2022
25. ZHANG S, You X, Zheng Y, Shen Y, et al
    The UBE2C/CDH1/DEPTOR axis is an oncogene-tumor suppressor cascade in lung cancer cells.
    J Clin Invest. 2022 Dec 22:e162434. doi: 10.1172/JCI162434.
    PubMed     Abstract available
    
    
    November 2022
26. LI K, Liu Y, Ding Y, Zhang Z, et al
    BCL6 is regulated by the MAPK/ELK1 axis and promotes KRAS-driven lung cancer.
    J Clin Invest. 2022;132.
    PubMed     Abstract available
    
    
    
27. ZHANG H, Zhu X, Friesen TJ, Kwak JW, et al
    Annexin A2/TLR2/MYD88 pathway induces arginase 1 expression in tumor-associated neutrophils.
    J Clin Invest. 2022;132.
    PubMed     Abstract available
    
    
    September 2022
28. NIE M, Chen N, Pang H, Jiang T, et al
    Targeting acetylcholine signaling modulates persistent drug tolerance in EGFR-mutant lung cancer and impedes tumor relapse.
    J Clin Invest. 2022 Sep 1. pii: 160152. doi: 10.1172/JCI160152.
    PubMed     Abstract available
    
    
    
29. WANG H, Lin Z, Nian Z, Zhang W, et al
    Hematopoietic transcription factor GFI1 promotes anchorage independence by sustaining ERK activity in cancer cells.
    J Clin Invest. 2022;132.
    PubMed     Abstract available
    
    
    August 2022
30. HE Y, Luo W, Liu Y, Wang Y, et al
    IL20RB mediates tumoral response to osteoclastic niches and promotes bone metastasis of lung cancer.
    J Clin Invest. 2022 Aug 25. pii: 157917. doi: 10.1172/JCI157917.
    PubMed     Abstract available
    
    
    June 2022
31. YAN D, Huelse JM, Kireev D, Tan Z, et al
    MERTK activation drives osimertinib resistance in EGFR-mutant non-small cell lung cancer.
    J Clin Invest. 2022 Jun 16. pii: 150517. doi: 10.1172/JCI150517.
    PubMed     Abstract available
    
    
    
32. DEFAYE M, Iftinca MC, Gadotti VM, Basso L, et al
    The neuronal tyrosine kinase receptor ligand ALKAL2 mediates persistent pain.
    J Clin Invest. 2022;132.
    PubMed     Abstract available
    
    
    May 2022
33. NANJO S, Wu W, Karachaliou N, Blakely CM, et al
    Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR mutant lung cancer.
    J Clin Invest. 2022 May 17. pii: 145099. doi: 10.1172/JCI145099.
    PubMed     Abstract available
    
    
    April 2022
34. WAARTS MR, Stonestrom AJ, Park YC, Levine RL, et al
    Targeting mutations in cancer.
    J Clin Invest. 2022;132.
    PubMed     Abstract available
    
    
    March 2022
35. XU C, Jin G, Wu H, Cui W, et al
    SIRPgamma-expressing cancer stem-like cells promote immune escape of lung cancer via Hippo signaling.
    J Clin Invest. 2022;132.
    PubMed     Abstract available
    
    
    February 2022
36. MANABE T, Bivona TG
    Remodeling of the tumor/tumor microenvironment ecosystem during KRAS G12C inhibitor clinical resistance in lung cancer.
    J Clin Invest. 2022;132.
    PubMed     Abstract available
    
    
    
37. TSAI YS, Woodcock MG, Azam SH, Thorne LB, et al
    Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition.
    J Clin Invest. 2022;132.
    PubMed     Abstract available
    
    
    November 2021
38. MA B, Akosman B, Kamle S, Lee CM, et al
    CHI3L1 regulates PD-L1 and anti-CHI3L1-PD-1 antibody elicits synergistic antitumor responses.
    J Clin Invest. 2021;131.
    PubMed     Abstract available
    
    
    October 2021
39. ZHANG W, Sun Y, Bai L, Zhi L, et al
    RBMS1 regulates lung cancer ferroptosis through translational control of SLC7A11.
    J Clin Invest. 2021 Oct 5. pii: 152067. doi: 10.1172/JCI152067.
    PubMed     Abstract available
    
    
    September 2021
40. HEISHIMA K, Sugito N, Soga T, Nishikawa M, et al
    Petasin potently inhibits mitochondrial complex I-based metabolism that supports tumor growth and metastasis.
    J Clin Invest. 2021;131.
    PubMed     Abstract available
    
    
    August 2021
41. SU SF, Ho H, Li JH, Wu MF, et al
    DNA methylome and transcriptome landscapes of cancer-associated fibroblasts reveal a smoking-associated malignancy index.
    J Clin Invest. 2021;131.
    PubMed     Abstract available
    
    
    May 2021
42. MAIMON A, Levi-Yahid V, Ben-Meir K, Halpern A, et al
    Myeloid cell-derived PROS1 inhibits tumor metastasis by regulating inflammatory and immune responses via IL-10.
    J Clin Invest. 2021;131.
    PubMed     Abstract available
    
    
    
43. LIANG W, Chen Z, Li C, Liu J, et al
    Accurate diagnosis of pulmonary nodules using a noninvasive DNA methylation test.
    J Clin Invest. 2021;131.
    PubMed     Abstract available
    
    
    January 2021
44. SEHGAL K, Barbie DA
    Targeting the mutant p53 secretome.
    J Clin Invest. 2021;131.
    PubMed     Abstract available
    
    
    
45. AMOEDO ND, Sarlak S, Obre E, Esteves P, et al
    Targeting the mitochondrial trifunctional protein restrains tumor growth in oxidative lung carcinomas.
    J Clin Invest. 2021;131.
    PubMed     Abstract available
    
    
    
46. CHO J, Min HY, Lee HJ, Hyun SY, et al
    RGS2-mediated translational control mediates cancer cell dormancy and tumor relapse.
    J Clin Invest. 2021;131.
    PubMed     Abstract available
    
    
    
47. TAN X, Shi L, Banerjee P, Liu X, et al
    A protumorigenic secretory pathway activated by p53 deficiency in lung adenocarcinoma.
    J Clin Invest. 2021;131.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.